BP 897 is a potent (K i = 0.92 nM) dopamine D 3 receptor compound developed for the treatment of cocaine abuse and craving. BP 897 has a high selectivity for the dopamine D 3 versus D 2 receptors (70-fold) and a moderate affinity for 5-HT 1A receptors, (K i = 84 nM), adrenergic-á 1 (K i = 60 nM) and -á 2 adrenoceptors (K i = 83 nM). BP 897 displays significant intrinsic activity at the human dopamine D 3 receptor by decreasing forskolin-stimulated cAMP levels and by stimulating mitogenesis of dopamine D 3 -expressing NG108-15 cells. Although these findings suggest that BP 897 is a partial agonist, recent studies in Chinese Hamster Ovary (CHO) cells with expressed dopamine D 3 receptors demonstrated that BP 897 is devoid of any intrinsic activity but potently inhibits dopamine agonist effects (pIC 50 = 9.43 and 9.51) in agonist-induced acidification rate or increase of GTPãS binding, respectively. In addition, BP 897 inhibits in vivo (EC 50 = 1.1 mg/kg, i.v.) agonist-induced decrease of firing rate of dopaminergic neurons in the substantia nigra.
